HORSHAM, Pa. - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology firm, has launched an initiative to extend insurance coverage for treatments of various skin conditions, including vitiligo and atopic dermatitis, which collectively affect millions of Americans.
The company is seeking to broaden the scope of Current Procedural Terminology (CPT) codes, aiming to enhance patient access to care and provider reimbursement rates.
The initiative focuses on phototherapy treatments under CPT codes 96920, 96921, and 96922, which relate to excimer laser procedures for treating skin areas of different sizes. STRATA is leveraging its patient database of over 270,000 individuals to support this advocacy effort.
In recent months, STRATA has sent more than 1,000 legislative support letters to congressional and senate delegates, advocating on behalf of patients. This action is part of a larger industry movement to reassess CPT codes and improve patient access to essential therapies.
Dr. Dolev Rafaeli, CEO of STRATA, emphasized the company's commitment to enhancing the quality of life for patients by ensuring they can access medically necessary treatments. Dr. Elisabeth G. Richard, a member of the Photodermatology Society and an Assistant Professor at Johns Hopkins University School of Medicine, highlighted the critical role of phototherapy in treating vitiligo, a condition affecting more than 1% of the population.
STRATA Skin Sciences develops and markets products for in-office treatment of dermatologic conditions such as psoriasis, vitiligo, and acne. Their portfolio includes the XTRAC excimer laser, VTRAC lamp systems, and the TheraClear X Acne Therapy System.
The company's approach includes a partnership program offering equipment installation, on-site training, service maintenance, and co-op advertising support, structured around a fee-per-treatment model.
This press release statement contains forward-looking statements, which are subject to uncertainties and changes, including the company's ability to expand insurance coverage and develop new products. The company has cautioned that actual results may differ from expectations due to various factors.
Information based on a press release statement from STRATA Skin Sciences, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.